What's new? Log in Free sign up

Antiviral Inactive 10-K2011 FY Annual report

Filed: 29 Mar 12, 12:00am

Content analysis

?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Baiguang, chapter, consecutive, convergence, District, enable, goodwill, Guangyi, Interactive, nonpublic, opposed, preceding, pursuit, reclassification, redeem, redeliberate, repurchase, setoff, simplify, supersede, threshold, transferor, website, wording, Xicheng

Removed: decision, portion, traded

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Antiviral similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

1

OMEGA BIO-PHARMA STATUS REPORT


Obio Pharmaceutical (H.K.) Limited
Antiviral Patents

OBI-104 Series
Characteristics: Basic and Broad Protection of Cysteamine's Antiviral Effects to Various Types of Viruses including Influenza Virus
Docket No.	Country	Assignee	Title	Serial No.	Inventors	Date Filed	Brief Description	Patent No.	Date Granted
OBI-104P	United States	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	60/541,893	(Liang, Chi)	2/3/2004	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C2P	United States	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Improving Immunity and Treating Stress	60/740,584	(Liang, Chi, Xu, Chan)	11/28/2005	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C3P	United States	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Improving Immunity and Treating Stress	60/810,773	(Liang, Chi, Xu, Chan)	6/2/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C4P	United States	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	60/818,885	(Liang, Chi, Xu, Chan)	7/6/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5P	United States	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	60/847,020	(Liang, Chi, Xu, Chan)	9/25/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 US	United States	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Viral Infections	11/605,551	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 PCT	PCT	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound	PCT/US2006/045652	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 AR	Argentina	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	P 06 01 05117	(Liang, Chi, Xu, Chan)	11/22/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 CL	Chile	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	2006-3290	(Liang, Chi, Xu, Chan)	11/27/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---

2

OMEGA BIO-PHARMA STATUS REPORT


OBI-104C5XC1 MY	Malaysia	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound	PI20064570	(Liang, Chi, Xu, Chan)	11/27/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	MY-141003-A	2/12/2010
OBI-104C5XC1 PK	Pakistan	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	1530/2006	(Liang, Chi, Xu, Chan)	11/18/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 TH	Thailand	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	0601005885	(Liang, Chi, Xu, Chan)	11/27/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 TW	Taiwan	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections	095143633	(Liang, Chi, Xu, Chan)	11/24/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 AP	ARIPO (African Regional Industrial Property Organization)	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	AP/P/2008/004511	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 AU	Australia	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	2006318355	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 BR	Brazil	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	PI0619377-3	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 CA	Canada	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	2,631,241	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 CN	China	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	200680044305.6	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	ZL200680044305.6	01/26/2011
OBI-104C5XC1 EG	Egypt	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	PCT 887/2008	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 EPO	Europe	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	06838553.3	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---

3

OMEGA BIO-PHARMA STATUS REPORT


OBI-104C5XC1 IN	India	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	4368/DELNP/2008	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 ID	Indonesia	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	W00200801613	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 IL	Israel	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	191705	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 JP	Japan	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	2008-542483	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 KR	South Korea	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	10-2008-7015869	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 MX	Mexico	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	MX/A/2008/006851	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 NZ	New Zealand	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	568464	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	568464	01/08/2011
OBI-104C5XC1 OA	OAPI (African Intellectual Property Organization)	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	1200800196	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	14186	12/30/2008
OBI-104C5XC1 PH	Philippines	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	1-2008-501113	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 RU	Russian Federation	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	2008126272	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	2431476	10/20/2011
OBI-104C5XC1 ZA	South Africa	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	2008/05191	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	2008/05191	8/26/2009

4

OMEGA BIO-PHARMA STATUS REPORT


OBI-104C5XC1 SG	Singapore	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	200803923-2	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XCDIV SG	Singapore	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (as amended)	201008769-0	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 AE	United Arab Emirates	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	523/2008	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 VN	Vietnam	Omega-BioPharma (H.K.) Ltd	Process of Using Cysteamine in Manufacture of Medicaments for Treating Virus Infection and the Compositions (as amended)	1-2008-01282	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---
OBI-104C5XC1 HK	Hong Kong	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Viral Infections with a Cysteamine Compound (As amended by the PCT)	09103170.7	(Liang, Chi, Xu, Chan)	11/28/2006	Cysteamine Compositions, and their use, for treating viruses, including Influenza Virus.	---	---

OBI-108 Series
Characteristics: Usage of Cysteamine as an Antiviral Drug together with Other Antiviral Drugs including Tamiflu and/or Vaccines. This patent's major purpose is to extend further Protection of OBI-104, Particularly on Influenza Virus
Docket No.	Country	Assignee	Title	Serial No.	Inventors	Date Filed	Brief Description	Patent No.	Date Granted
OBI-108P	United States Provisional	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Influenza Infections	US60/940,255	Liang, Chi, Xu, Chan	5/25/2007	Combination treatments using cysteamine and other agents for treating of viruses including Influenza Virus.	---	---
OBI-108X PCT	PCT	Omega-BioPharma (HK) Ltd	Materials and Methods for Treating Influenza Infections	PCT/US2008/064860	Liang, Chi, Xu, Chan	5/27/2008	Combination treatments using cysteamine and other agents for treating of viruses including Influenza Virus.	---	---
OBI-108X US	United States	Omega-BioPharma (H.K.) Ltd	Materials and Methods for Treating Influenza Infections	12/600,264	Liang, Chi, Xu, Chan	1/13/2010	Combination treatments using cysteamine and other agents for treating of viruses including Influenza Virus.	---	---
OBI-108X JP	Japan	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Influenza Infections	2010-509585	Liang, Chi, Xu, Chan	5/27/2008	Combination treatments using cysteamine and other agents for treating of viruses including Influenza Virus.	---	---

5

OMEGA BIO-PHARMA STATUS REPORT


OBI-111 Series
Characteristics: This is more detailed application usage of Cysteamine to Treat Influenza virus through an Inhalation of Cysteamine directly to the Respiratory Tract, the exact location where the Influenza Virus attacks. Please refer to another inhalation Influenza drug "RELENZA" same principle. This patent, again, is to further enhance and extend the Protection of OBI-104.
Docket No.	Country	Assignee	Title	Serial No.	Inventors	Date Filed	Brief Description	Patent No.	Date Granted
OBI-111P	United States Provisional	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Viral Infections	61/180,840	Thoene	5/23/2009	Inhalation Antiviral treatments including for the treatment of Influenza virus.	---	---
OBI-111X US	United States	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Viral Infections	13/302,620	Thoene	11/22/2011	Inhalation Antiviral treatments including for the treatment of Influenza virus.	---	---
OBI-111X PCT	WIPO	Obio Pharmaceutical (H.K.) Ltd	Materials and Methods for Treating Viral Infections	PCT/US2010/035785	Thoene	5/21/2010	Inhalation Antiviral treatments including for the treatment of Influenza virus.	---	---

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.